^
    Apply
    Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma (NCT05241392)
    Phase 1
    Beijing Tiantan Hospital
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    01/27/2022
    Primary completion :
    11/30/2024
    Completion :
    12/31/2026
    CD276
    Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma. (NCT06482905)
    Phase 1
    Tcelltech Inc.
    Recruiting
    Last update posted :
    01/08/2025
    Initiation :
    09/04/2024
    Primary completion :
    09/01/2026
    Completion :
    06/01/2027
    IFNG • IL6 • TNFA • IL2 • IL10
    Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors (NCT06612645)
    Phase 1
    Chulalongkorn University
    Not yet recruiting
    Last update posted :
    12/09/2024
    Initiation :
    12/01/2024
    Primary completion :
    12/01/2026
    Completion :
    12/01/2027
    IFNG • IL6 • CD276 • TNFA • IL2 • IL7R • IL10
    WL276 CAR-T Cell Therapy for CD276 Positive Recurrent or Progressive Glioblastoma Patients (NCT06691308)
    Phase 1
    Beijing Immunochina Medical Science & Technolog...
    Not yet recruiting
    Last update posted :
    11/18/2024
    Initiation :
    11/12/2024
    Primary completion :
    05/31/2027
    Completion :
    05/31/2027
    CD276
    Autologous CAR-T Cells Targeting B7-H3 in PDAC (NCT06158139)
    Phase 1
    UNC Lineberger Comprehensive Cancer Center
    Not yet recruiting
    Last update posted :
    04/23/2024
    Initiation :
    06/01/2024
    Primary completion :
    06/01/2026
    Completion :
    06/01/2028
    CD276
    |
    CAR.B7-H3 T
    Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc (NCT05366179)
    Phase 1
    UNC Lineberger Comprehensive Cancer Center
    Recruiting
    Last update posted :
    04/23/2024
    Initiation :
    09/02/2022
    Primary completion :
    10/31/2024
    Completion :
    05/01/2030
    CD276
    |
    CAR.B7-H3 T
    B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (STRIvE-02) (NCT04483778)
    Phase 1
    Seattle Children's Hospital
    Active, not recruiting
    Last update posted :
    04/23/2024
    Initiation :
    07/13/2020
    Primary completion :
    12/01/2025
    Completion :
    12/01/2040
    CD276
    |
    CD276 expression • CD19 expression
    |
    Keytruda (pembrolizumab) • SCRI-CARB7H3(s) • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1
    Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian (NCT04670068)
    Phase 1
    UNC Lineberger Comprehensive Cancer Center
    Recruiting
    Last update posted :
    04/23/2024
    Initiation :
    01/27/2021
    Primary completion :
    02/01/2025
    Completion :
    02/01/2030
    CD276 • BRCA • MUC16
    |
    BRCA mutation
    |
    cyclophosphamide • fludarabine IV • CAR.B7-H3 T • cyclophosphamide intravenous
    Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG (CMD03DIPG) (NCT06221553)
    Phase 1
    Chulalongkorn University
    Recruiting
    Last update posted :
    04/19/2024
    Initiation :
    03/01/2024
    Primary completion :
    03/01/2026
    Completion :
    09/01/2026
    CD276 • IL7R
    Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors (NCT05835687)
    Phase 1
    St. Jude Children's Research Hospital
    Recruiting
    Last update posted :
    03/13/2024
    Initiation :
    04/27/2023
    Primary completion :
    03/01/2028
    Completion :
    03/01/2028
    CD276
    |
    B7-H3 CAR-T
    Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors (NCT04185038)
    Phase 1
    Seattle Children's Hospital
    Recruiting
    Last update posted :
    12/20/2023
    Initiation :
    12/11/2019
    Primary completion :
    05/01/2026
    Completion :
    05/01/2041
    CD276
    |
    CD276 expression
    |
    SCRI-CARB7H3(s)
    Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection (NCT06018363)
    Phase 1/2
    Dushu Lake Hospital Affiliated to Soochow Unive...
    Recruiting
    Last update posted :
    08/30/2023
    Initiation :
    06/01/2023
    Primary completion :
    12/31/2025
    Completion :
    12/31/2026
    IL6 • CD276 • IL10
    |
    CD276 expression
    |
    QH104
    B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) (NCT04897321)
    Phase 1
    St. Jude Children's Research Hospital
    Recruiting
    Last update posted :
    08/08/2023
    Initiation :
    07/06/2022
    Primary completion :
    03/01/2026
    Completion :
    03/01/2027
    CD276
    |
    CD276 expression
    |
    cyclophosphamide • fludarabine IV • mesna • B7-H3 CAR-T • cyclophosphamide intravenous
    Safety and Efficacy of Targeted IL-13 Rα2 or B7-H3 UCAR-T for Advanced Glioma (NCT05752877)
    Phase N/A
    Second Affiliated Hospital of Soochow University
    Recruiting
    Last update posted :
    03/03/2023
    Initiation :
    05/01/2021
    Primary completion :
    04/30/2026
    Completion :
    04/30/2026
    PD-L1 • CD276
    |
    MT-026 • MT027
    EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer (NCT05341492)
    Phase 1
    Second Affiliated Hospital of Guangzhou Medical...
    Recruiting
    Last update posted :
    02/28/2023
    Initiation :
    05/01/2022
    Primary completion :
    05/01/2025
    Completion :
    05/01/2025
    EGFR • CD276
    |
    EGFR expression • CD276 expression
    |
    Undisclosed EGFR/B7H3 CAR-T
    TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma (NCT05562024)
    Phase 1
    PersonGen BioTherapeutics (Suzhou) Co., Ltd.
    Recruiting
    Last update posted :
    02/27/2023
    Initiation :
    12/30/2022
    Primary completion :
    12/18/2025
    Completion :
    02/18/2039
    CD276
    |
    TAA6-CAR-T
    UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (NCT05731219)
    Phase 1
    PersonGen BioTherapeutics (Suzhou) Co., Ltd.
    Recruiting
    Last update posted :
    02/16/2023
    Initiation :
    09/26/2022
    Primary completion :
    09/26/2023
    Completion :
    09/26/2025
    CD276
    |
    CD276 expression
    |
    UTAA06
    GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers (NCT03198052)
    Phase 1
    Second Affiliated Hospital of Guangzhou Medical...
    Recruiting
    Last update posted :
    02/14/2023
    Initiation :
    07/01/2017
    Primary completion :
    08/01/2024
    Completion :
    08/01/2026
    EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA
    |
    MSLN expression • EGFR positive • GPC3 expression
    |
    GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells
    Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (NCT05722171)
    Phase 1
    PersonGen BioTherapeutics (Suzhou) Co., Ltd.
    Recruiting
    Last update posted :
    02/10/2023
    Initiation :
    12/27/2022
    Primary completion :
    12/27/2023
    Completion :
    12/27/2024
    CD276
    |
    CD276 expression
    |
    UTAA06
    Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma (NCT04385173)
    Phase 1
    Second Affiliated Hospital, School of Medicine,...
    Recruiting
    Last update posted :
    12/28/2022
    Initiation :
    12/01/2022
    Primary completion :
    03/01/2024
    Completion :
    05/01/2024
    CD276
    |
    temozolomide • Airuituo (bevacizumab biosimilar) • BP102
    B7-H3 CAR-T for Recurrent or Refractory Glioblastoma (NCT04077866)
    Phase 1/2
    Second Affiliated Hospital, School of Medicine,...
    Recruiting
    Last update posted :
    12/28/2022
    Initiation :
    06/01/2023
    Primary completion :
    06/01/2025
    Completion :
    08/01/2025
    CD276
    |
    temozolomide • BP102
    B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors (NCT05515185)
    Phase 1
    The First People's Hospital of Lianyungang
    Not yet recruiting
    Last update posted :
    08/25/2022
    Initiation :
    09/09/2022
    Primary completion :
    09/08/2024
    Completion :
    09/08/2024
    CD276
    |
    cyclophosphamide • fludarabine IV • KT095
    Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer (NCT05323201)
    Phase 1/2
    The Affiliated Hospital of Xuzhou Medical Unive...
    Recruiting
    Last update posted :
    04/12/2022
    Initiation :
    02/10/2022
    Primary completion :
    02/10/2024
    Completion :
    02/10/2027
    CD276
    |
    CD276 expression
    |
    cyclophosphamide • fludarabine IV • fhB7H3.CAR-Ts
    Study of Fully Human B7H3 CAR-T in Treating Recurrent Malignant Ovarian Cancer (NCT05211557)
    Phase 1/2
    The Affiliated Hospital of Xuzhou Medical Unive...
    Recruiting
    Last update posted :
    01/27/2022
    Initiation :
    11/16/2021
    Primary completion :
    08/31/2023
    Completion :
    08/31/2026
    CD276 • MUC16
    |
    CD276 expression
    |
    cyclophosphamide • fhB7H3.CAR-Ts
    A Clinical Trial of TAA06 Injection in Advanced Solid Tumors (NCT05190185)
    Phase 1
    PersonGen BioTherapeutics (Suzhou) Co., Ltd.
    Recruiting
    Last update posted :
    01/13/2022
    Initiation :
    06/01/2021
    Primary completion :
    12/01/2023
    Completion :
    12/01/2023
    CD276
    |
    TAA6-CAR-T
    CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer (CAR-T) (NCT05143151)
    Phase 1/2
    Shenzhen University General Hospital
    Recruiting
    Last update posted :
    12/03/2021
    Initiation :
    07/01/2021
    Primary completion :
    06/01/2024
    Completion :
    07/01/2024
    CD276 • BRCA
    |
    CD276 expression
    |
    CD276 CAR-T
    Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor (NCT04864821)
    Phase 1
    PersonGen BioTherapeutics (Suzhou) Co., Ltd.
    Not yet recruiting
    Last update posted :
    05/06/2021
    Initiation :
    05/14/2021
    Primary completion :
    05/14/2022
    Completion :
    05/14/2023
    CD276
    |
    CD276 expression
    |
    TAA6-CAR-T
    4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma (NCT04637503)
    Phase 1/2
    Shenzhen Geno-Immune Medical Institute
    Recruiting
    Last update posted :
    11/19/2020
    Initiation :
    11/18/2020
    Primary completion :
    11/19/2020
    Completion :
    12/31/2023
    CD276
    |
    4SCAR-T • GD2, PSMA and CD276 CAR-T
    Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276 (NCT04432649)
    Phase 1/2
    Shenzhen Geno-Immune Medical Institute
    Recruiting
    Last update posted :
    06/16/2020
    Initiation :
    06/01/2020
    Primary completion :
    05/31/2023
    Completion :
    05/31/2024
    CD276
    |
    4SCAR-276